tafamidis ATTR Vyndamax
Selected indexed studies
- Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study. (Eur J Heart Fail, 2021) [PMID:33070419]
- Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. (N Engl J Med, 2018) [PMID:30145929]
- Cardiac Amyloidosis Due to Transthyretin Protein: A Review. (JAMA, 2024) [PMID:38441582]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. (2018) pubmed
- Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy. (2022) pubmed
- Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study. (2021) pubmed
- Tafamidis Efficacy Among Octogenarian Patients in the Phase 3 ATTR-ACT and Ongoing Long-Term Extension Study. (2024) pubmed
- Effect of Tafamidis on Cardiac Function in Patients With Transthyretin Amyloid Cardiomyopathy: A Post Hoc Analysis of the ATTR-ACT Randomized Clinical Trial. (2024) pubmed
- Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments. (2015) pubmed
- Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy. (2025) pubmed
- New therapies to treat cardiac amyloidosis. (2025) pubmed
- Cardiac Amyloidosis Due to Transthyretin Protein: A Review. (2024) pubmed
- Tafamidis in Octogenarians: An ATTR-ACT-ive Choice. (2024) pubmed